First Week Of PDLI September 21st Options Trading

Investors in PDL BioPharma Inc ( PDLI) saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PDLI options chain for the new September 21st contracts and identified the following put contract of particular interest.

The put contract at the $8.00 strike price has a current bid of 30 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $8.00, but will also collect the premium, putting the cost basis of the shares at $7.70 (before broker commissions). To an investor already interested in purchasing shares of PDLI, that could represent an attractive alternative to paying $8.12/share today.

Because the $8.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 54%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.75% return on the cash commitment, or 22.81% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for PDL BioPharma Inc, and highlighting in green where the $8.00 strike is located relative to that history:

If you liked this article you might like

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)